An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials | Zendy

Marc Morris | Zendy; P. W. Lane | Zendy; Kwan S. Lee | Zendy; Daniel Parks | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

An Integrated Analysis of Liver Safety Data from Orlistat Clinical Trials

Author(s) -

Marc Morris,

P. W. Lane,

Kwan S. Lee,

Daniel Parks

Publication year - 2012

Publication title -

obesity facts

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.398

H-Index - 45

eISSN - 1662-4033

pISSN - 1662-4025

DOI - 10.1159/000341589

Subject(s) - orlistat , medicine , placebo , adverse effect , liver injury , odds ratio , adverse event reporting system , liver function , gastroenterology , obesity , weight loss , pathology , alternative medicine

Orlistat is an oral gastrointestinal lipase inhibitor and is indicated for treatment of obesity in combination with a hypocaloric diet. Post-marketing reports of adverse reactions revealed hints for possible drug-induced liver injury which has prompted changes to the product information. Orlistat's development program, involving over 30,000 patients, did not indicate a hepatic safety issue.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research